Skip to main content

Table 3 Adjusted hazard ratios for site-specific cancer development

From: The risk of newly diagnosed cancer in patients with rheumatoid arthritis by TNF inhibitor use: a nationwide cohort study

Cancer Site

Event number

aHR (95% CI)

Before-matching cohort

Matched cohort

Before-matching cohort

Matched cohort

TNF inhibitor cohort (12,491.9 PY)

nbDMARD cohort (117,735.9 PY)

TNF inhibitor cohort (8884.8 PY)

nbDMARD cohort (8422.2 PY)

(130,227.8 PY)

(17,307.0 PY)

All cancer

81

1769

58

131

0.492 (0.351, 0.688)

0.379 (0.255, 0.563)

Oropharyngeal cavity

0

14

0

1

-

-

GI tract

25

536

18

41

0.432 (0.235, 0.797)

0.670 (0.367, 1.223)

 Upper GI tract

8

149

7

11

0.846 (0.296, 2.421)

-

 Colon and rectum

9

163

6

14

0.385 (0.132, 1.124)

-

 Liver

4

159

3

12

0.377 (0.088, 1.616)

-

 Biliary tract

6

106

3

5

0.372 (0.096, 1.436)

-

Respiratory system

19

308

13

13

0.762 (0.382, 1.522)

1.371 (0.458, 4.109)

Bone and soft tissue

1

4

0

0

8.366 (0.325, 215.255)

-

Skin

2

57

1

4

0.159 (0.014, 1.858)

-

 Melanoma

1

5

0

0

0.126 (0.001, 20.528)

-

 Non-melanoma

1

52

1

4

0.505 (0.023, 11.019)

-

Breast

8

316

7

58

0.146 (0.045, 0.474)

0.748 (0.090, 6.221)

Gynecologic system

8

95

6

7

1.970 (0.660, 5.883)

-

Genitourinary system

6

181

3

7

0.220 (0.059, 0.820)

-

Central nervous system

0

12

0

1

-

-

Endocrine system

9

164

8

31

0.901 (0.331, 2.456)

0.518 (0.078, 3.454)

Hematologic system

1

140

0

13

0.011 (0, 1.037)

-

 Lymphoma

0

58

0

6

-

-

  1. aHR adjusted hazard ratio, CI confidence interval, TNF tumor necrosis factor, nbDMARDs non-biologic disease-modifying anti-rheumatic drugs; PY person-years; GI gastrointestinal